ASAdriana Sarb

Adriana Sarb

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adriana Sarb has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Papillary muscles, ventricular loading, and atrial remodelling as beat-to-beat determinants of functional mitral regurgitation: an exploratory Granger causality study

    by Csilla Andrea Eotvos, Teodora Avram, Eric Daniel Blendea, Matei Ioan Munteanu, Adrian Florin Bubuianu, Madalina Patricia Moldovan, Petra Hedesiu, Roxana Daiana Lazar, Iulia Georgiana Zehan, Adriana Daniela Sarb, et al.

    Background: Functional mitral regurgitation results from interacting mechanisms whose contributions vary between atrial and ventricular subtypes and shift within each heartbeat, producing temporal patterns static analyses cannot capture. Objectives: To identify which structural determinants predict mitral regurgitation variability beat to beat using Granger causality within vector autoregression, focusing on papillary muscle dynamics across subtypes. Methods: Frame-level echocardiographic time series from 41 patients (21 atrial, 20 ventricular; 1,959 frames) were z-score standardised within patient. Individual (lag 3) and pooled panel vector autoregression models, with supplementary full-cycle analysis across lags 1–20, tested whether LV volume, left atrial volume, papillary muscle length, and annulus diameter Granger-predict mitral regurgitation area. Results: Individual models revealed marked heterogeneity. In pooled analysis, LV volume was the strongest Granger predictor at the shortest lag (atrial p=0.011; ventricular p=0.006), while left atrial volume reached significance at longer lags (lag 6 atrial p=0.033, ventricular p=0.004). Systolic papillary muscle length was not predictive at any lag. Full-cycle analysis revealed an asymmetric subtype dissociation: papillary muscle length Granger-predicted regurgitation only in the ventricular subtype (lag 1 p<0.001) whereas regurgitation predicted papillary muscle deformation at every lag in the atrial subtype (20/20) but at none in the ventricular subtype. Cross-sectional comparisons of the four determinants did not distinguish MR severity within subtypes. Conclusions: Beat-to-beat vector autoregression and Granger modelling reveals heterogeneous, subtype-specific temporal patterns and a strong directional asymmetry between regurgitation and papillary muscle dynamics across subtypes. This disease-agnostic framework may support patient-specific temporal phenotyping of functional mitral regurgitation. Graphical

  • Open Access

    Angiographic Anatomy of the Left Coronary Veins: Beyond Conventional Cardiac Resynchronization Therapy

    by Iulia-Georgiana Zehan, Csilla-Andrea Eötvös, Mădălina Patricia Moldovan, Mihai-Gabriel Andrei, Călina-Patricia Șchiop-Țentea, Roxana Daiana Lazar, Adriana Daniela Sârb, Giorgia CoșEriu, Teodora Avram, Adela Șerban, et al.

    Purpose of Review: This review aims to synthesize current knowledge on the angiographic anatomy of the coronary sinus and its tributaries veins, with focus on venous branches other than classical ones used in cardiac resynchronization therapy. It also presents common anatomical aspects that could impact the clinical outcome. Recent Findings: Recent advancements in the electrophysiology field, like epicardial arrhythmia mapping and ablation through coronary sinus or cardiac pacing from atypical veins requires a detailed angiographic assessment of cardiac veins. There is an increased interest for the veins coursing in the left ventricular summit (LVS) area and could potentially provide a pathway to reach the LVS arrhythmogenic foci. However, there is no consensus regarding the nomenclature and classification of these veins. Summary: This review could offer a better understanding of the coronary sinus and its tributary veins distribution, dimensions and relationship with nearby structures that could help the development of new ablation and pacing tools and strategies, with higher success rates.


  • Open Access

    Left atrial appendage morphology and mitral annular plane systolic excursion predict stroke in patients with atrial fibrillation and high thromboembolic risk

    by A Sarb, R D Lazar, I G Zehan, C P Schiop-Tentea, G Coseriu, C A Apetrei, M Moldovan, L Mocanu, M Jelnean, O F Sarb, et al.

    Background: Previous research has revealed a relationship between the morphology and function of the left atrial appendage (LAA) and the rate of thromboembolic events in patients with atrial fibrillation (AF). There is limited data on the impact of the left ventricular (LV) function on LAA thrombus formation. Emptying of the LAA depends on the active contraction of this structure as well as on the passive motion due to external compression from the LV base during ventricular diastole. Purpose: Given these considerations the goal of this study was to investigate by transesophageal and transthoracic echocardiography the morphology and function of the LAA in relationship with the LV function and to assess the impact on incidence of stroke in a group of patients with AF with high thromboembolic risk who underwent TEE-guided direct current cardioversion. Methods: We included 148 patients (age 65 ±11 yrs, 79men, median CHA2DS2-VASc score 4 (IQR 2-6), left ventricular ejection fraction 48±11%), who underwent transesophageal echocardiography before cardioversion. During a median follow-up period of 23 months (range 1-107) 34 patients developed stroke or TIA. Results: The distribution of the four LAA morphologies (Figure 1) was: Cactus [47 (32%)], Cauliflower [30 (20%)], Windsock [38(26%)], and Chicken Wing [33 (22%)]. During the follow-up period stroke/TIA occurred significantly more frequently in patients with cactus or cauliflower LAA morphology vs. patients with windsock or chicken wing morphology (25 (35%) vs 9 (11%); p value=0.001). Patients who developed stroke or TIA had significantly lower MAPSE vs patients with event free survival (8±3 vs 12±3mm; p value=0.001). Kaplan-Meier survival curves for different categories of MAPSE and LAA morphology are shown in Figure 2. The significant relationship between MAPSE and stroke-free survival was retained in Cox multivariable analysis that included LAA morphology, CHA2DS2-VASc score and AF types. This association was present whether MAPSE was entered into the multivariable model as a continuous or dichotomized variable. Conclusions: In patients with high thromboembolic risk, MAPSE predicts the occurrence of stroke independent of LAA morphology and CHA2DS2-VASc score. This phenomenon could be related to the impact LV diastole on LAA emptying.

  • Open Access

    Cognitive Dysfunction and Affective Mood Disorder Screening in Patients With Chronic Inflammatory Bowel Disease: Protocol for a Prospective Case-Control Study

    by Oliviu Florentiu Sarb, Vitalie Vacaras, Adriana Sarb, Maria Iacobescu, Alina-Ioana Tantau

    Background: Mild cognitive impairment (MCI) and Alzheimer’s disease (AD) might be more frequent in patients with inflammatory bowel disease (IBD), but the relationship between these 2 entities is yet to be entirely established. Certain blood biomarkers (eg, serum amyloid A [SAA] and serum homocysteine [Hcy], which increase in IBD and MCI; brain-derived neurotrophic factor [BDNF], which decreases in MCI and AD but is not clearly modified in IBD; and S100 calcium-binding protein B [S100B], which increases in the blood-brain barrier and neuronal lesions) might predict the stage of MCI or dementia or progression to a further state. The gut–brain axis (GBA) might be the key to the development of MCI in patients with IBD, along with systemic inflammation and the possible and unknown adverse effects of disease-modifying medication. Objective: The aim of this study is to investigate whether GBA interactions play a role in MCI development in patients with IBD. Methods: A case-control study will be conducted on at least 100 patients diagnosed with IBD, matched with 100 healthy individual controls. The matching will include sex, age, and education. Patients will be fully examined, and a full interview and a neurological and cognitive examination will be performed. The primary clinical outcomes will be cognitive test scores (Montreal Cognitive Assessment, Trail Making Test, Digit Symbol Substitution Test, forward and backward digit span testing). Depression, stress, and anxiety screening will also be performed. Blood samples from all participants will be collected, and aliquots will be immediately stored in a biobank. Primary laboratory outcomes will include serum levels of presumed cognitive dysfunction blood biomarkers SAA, Hcy, S100B, and BDNF. Follow-up will be performed at 12, 24, 36, and 48 months. Results: Data collection started in December 2021 and is ongoing. So far, 53 patients with IBD have been recruited and 50 HC matched. Data collection should end in January 2030. Intermediary analysis will be performed in April 2024. We expect patients with IBD to have lower scores on cognitive testing and a positive correlation between disease length and cognitive impairment level. In addition, the levels of stress, anxiety, and depression should be higher in the IBD group. The serum levels of the 4 biomarkers could correlate or anticorrelate with cognitive scores and serve as predictive factors for MCI or dementia development. A higher level of education, a younger age, the absence of malabsorption, and good disease control might serve as protectors against MCI. Conclusions: GBA interactions, along with systemic inflammation and the adverse effects of medication, might be a cause of MCI and AD development in patients with IBD. Serum biomarkers could prove cheap and useful predictors of MCI development. Trial Registration: ClinicalTrials.gov NCT05760729; https://clinicaltrials.gov/study/NCT05760729 International Registered Report Identifier (IRRID): DERR1-10.2196/50546


  • Open Access

    Cognitive Dysfunction and Affective Mood Disorder Screening in Patients With Chronic Inflammatory Bowel Disease: Protocol for a Prospective Case-Control Study (Preprint)

    by Oliviu Florentiu Sarb, Vitalie Vacaras, Adriana Sarb, Maria Iacobescu, Alina-Ioana Tantau

    BACKGROUND Mild cognitive impairment (MCI) and Alzheimer’s disease (AD) might be more frequent in patients with inflammatory bowel disease (IBD), but the relationship between these 2 entities is yet to be entirely established. Certain blood biomarkers (eg, serum amyloid A [SAA] and serum homocysteine [Hcy], which increase in IBD and MCI; brain-derived neurotrophic factor [BDNF], which decreases in MCI and AD but is not clearly modified in IBD; and S100 calcium-binding protein B [S100B], which increases in the blood-brain barrier and neuronal lesions) might predict the stage of MCI or dementia or progression to a further state. The gut–brain axis (GBA) might be the key to the development of MCI in patients with IBD, along with systemic inflammation and the possible and unknown adverse effects of disease-modifying medication. OBJECTIVE The aim of this study is to investigate whether GBA interactions play a role in MCI development in patients with IBD. METHODS A case-control study will be conducted on at least 100 patients diagnosed with IBD, matched with 100 healthy individual controls. The matching will include sex, age, and education. Patients will be fully examined, and a full interview and a neurological and cognitive examination will be performed. The primary clinical outcomes will be cognitive test scores (Montreal Cognitive Assessment, Trail Making Test, Digit Symbol Substitution Test, forward and backward digit span testing). Depression, stress, and anxiety screening will also be performed. Blood samples from all participants will be collected, and aliquots will be immediately stored in a biobank. Primary laboratory outcomes will include serum levels of presumed cognitive dysfunction blood biomarkers SAA, Hcy, S100B, and BDNF. Follow-up will be performed at 12, 24, 36, and 48 months. RESULTS Data collection started in December 2021 and is ongoing. So far, 53 patients with IBD have been recruited and 50 HC matched. Data collection should end in January 2030. Intermediary analysis will be performed in April 2024. We expect patients with IBD to have lower scores on cognitive testing and a positive correlation between disease length and cognitive impairment level. In addition, the levels of stress, anxiety, and depression should be higher in the IBD group. The serum levels of the 4 biomarkers could correlate or anticorrelate with cognitive scores and serve as predictive factors for MCI or dementia development. A higher level of education, a younger age, the absence of malabsorption, and good disease control might serve as protectors against MCI. CONCLUSIONS GBA interactions, along with systemic inflammation and the adverse effects of medication, might be a cause of MCI and AD development in patients with IBD. Serum biomarkers could prove cheap and useful predictors of MCI development. CLINICALTRIAL ClinicalTrials.gov NCT05760729; https://clinicaltrials.gov/study/NCT05760729 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/50546